newsfilter
← Latest News
GlobeNewswire·

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies, and systemic sclerosis